| scholarly article | Q13442814 |
| P50 | author | Harvey M. Friedman | Q89912954 |
| Jessica B Flechtner | Q42200955 | ||
| Lauren M. Hook | Q42230866 | ||
| P2093 | author name string | Sita Awasthi | |
| Deborah Long | |||
| Jonathan Dubin | |||
| P2860 | cites work | Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group | Q78082370 |
| Blocking antibody access to neutralizing domains on glycoproteins involved in entry as a novel mechanism of immune evasion by herpes simplex virus type 1 glycoproteins C and E | Q24646778 | ||
| Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120 | Q27678306 | ||
| Repertoire of epitopes recognized by serum IgG from humans vaccinated with herpes simplex virus 2 glycoprotein D | Q33900262 | ||
| Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes | Q34057952 | ||
| Herpes simplex virus type 1 and 2 glycoprotein C prevents complement-mediated neutralization induced by natural immunoglobulin M antibody. | Q34545821 | ||
| An HSV-2 Trivalent Vaccine Is Immunogenic in Rhesus Macaques and Highly Efficacious in Guinea Pigs. | Q34549656 | ||
| Dissection of the antibody response against herpes simplex virus glycoproteins in naturally infected humans | Q34593833 | ||
| The herpes simplex virus 1 IgG fc receptor blocks antibody-mediated complement activation and antibody-dependent cellular cytotoxicity in vivo | Q34742635 | ||
| Efficacy results of a trial of a herpes simplex vaccine | Q35780697 | ||
| Immunodominant "asymptomatic" herpes simplex virus 1 and 2 protein antigens identified by probing whole-ORFome microarrays with serum antibodies from seropositive asymptomatic versus symptomatic individuals | Q35868029 | ||
| Discovery of potential diagnostic and vaccine antigens in herpes simplex virus 1 and 2 by proteome-wide antibody profiling | Q35868054 | ||
| Exploiting the defensive sugars of HIV-1 for drug and vaccine design | Q36802333 | ||
| A novel function of the herpes simplex virus type 1 Fc receptor: participation in bipolar bridging of antiviral immunoglobulin G. | Q36831366 | ||
| Blocking Immune Evasion as a Novel Approach for Prevention and Treatment of Herpes Simplex Virus Infection | Q37060288 | ||
| Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs | Q37547107 | ||
| Status of prophylactic and therapeutic genital herpes vaccines | Q38196195 | ||
| A trivalent subunit antigen glycoprotein vaccine as immunotherapy for genital herpes in the guinea pig genital infection model | Q40210971 | ||
| Glycoprotein C of herpes simplex virus type 1 prevents complement-mediated cell lysis and virus neutralization | Q41726663 | ||
| Identification of novel virus-specific antigens by CD4⁺ and CD8⁺ T cells from asymptomatic HSV-2 seropositive and seronegative donors | Q42200895 | ||
| Carbohydrate determinant NeuAc-Galbeta(1-4) of N-linked glycans modulates the antigenic activity of human immunodeficiency virus type 1 glycoprotein gp120 | Q43446688 | ||
| Implications for herpes simplex virus vaccine strategies based on antibodies produced to herpes simplex virus type 1 glycoprotein gC immune evasion domains | Q45453302 | ||
| Mechanism of complement inactivation by glycoprotein C of herpes simplex virus | Q45764786 | ||
| Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes | Q57076537 | ||
| Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation | Q59062494 | ||
| P433 | issue | 4 | |
| P921 | main subject | evasion of host immune response | Q1660157 |
| P304 | page(s) | 664-669 | |
| P577 | publication date | 2018-12-12 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | A trivalent gC2/gD2/gE2 vaccine for herpes simplex virus generates antibody responses that block immune evasion domains on gC2 better than natural infection | |
| P478 | volume | 37 |
| Q90700306 | A vaccine containing highly purified virus particles in adjuvant provides high level protection against genital infection and disease in guinea pigs challenged intravaginally with homologous and heterologous strains of herpes simplex virus type 2 |
| Q92462186 | Antibody responses to crucial functional epitopes as a novel approach to assess immunogenicity of vaccine adjuvants |
| Q89574699 | Intramuscular vaccination of mice with the human herpes simplex virus type-1(HSV-1) VC2 vaccine, but not its parental strain HSV-1(F) confers full protection against lethal ocular HSV-1 (McKrae) pathogenesis |
| Q90196797 | Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes |
| Q91760722 | Therapeutic Mucosal Vaccination of Herpes Simplex Virus 2-Infected Guinea Pigs with Ribonucleotide Reductase 2 (RR2) Protein Boosts Antiviral Neutralizing Antibodies and Local Tissue-Resident CD4+ and CD8+ TRM Cells Associated with Protection agains |
| Q90437526 | Trivalent glycoprotein subunit vaccine prevents neonatal herpes simplex virus mortality and morbidity |
Search more.